---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011607"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-21T00:53:04.680244+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProPhase Q1 net loss narrows to $4.7M, cuts costs, eyes Nebula sale, $50M recovery

## Summary
- Q1 net revenue $1.4M (down from $2.4M YoY); net loss $4.7M ($0.13/shr) vs $5.5M loss ($0.32/shr) last year.
- Headcount slashed from 96 to 25; Pharmaloz divested for ~$23M, genomics lab closed, saving >$6M annually.
- Engaged ThinkEquity to sell Nebula Genomics; 16-petabyte DNA dataset; sale expected within 3-4 months.
- Crown Medical expects ~$50M in insurance recoveries; company carries $20M A/R for this initiative.
- BE-Smart esophageal test submitted for peer review; LDT rule vacated by federal judge on Apr 1, 2025.

## SEC filing metadata
- accession: 0001641172-25-011607
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000164117225011607/0001641172-25-011607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000164117225011607/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011607
- JSON: https://secwatch.observer/filing/0001641172-25-011607.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011607.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.